CAS: 913835-98-0; (6-(Hydroxymethyl)Pyridin-3-yl)Boronic Acid
该化合物是一种有机有机体化合物,其特征是附于一个丙烯环上的碳酸功能组的存在;该化合物的特征是位于丙烯酮的6位置上的氢氧化甲基组,这增强了其溶性与再活性;已知的博诺酸具有与二醇形成可逆共价结合的能力,使其在各种应用中,包括在有机合成,医药化学和制药的构件中具有价值;该氢氧甲基组的存在还有助于其生物活动以及与生物分子的潜在互动;此外,该化合物可能具有中度酸性,例如由于该丙烯酸组而具有的中度酸性,它可以参与交叉的反相交反应,而这种反应对于形成碳结系至关重要.
相似化合物
1072945-86-8 913836-11-0 659742-21-9物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
CAS号88139-91-7 5-溴-2-吡啶甲醇 | CAS号73183-34-3 双戊酰二硼 | CAS号29682-15-3 5-溴吡啶-2-羧酸甲酯合成工艺路线路线简述
📜5-溴吡啶-2-羧酸甲酯置于sodium Tetrahydroborate,1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物,乙醇,Potassium Acetate体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,化学反应 18.0H,反应生成 6-(羟甲基)砒啶-3-硼酸
参考文献: Hydroxymethylaryl-Substituted Pyrrolotriazines As Alk1 Inhibitors[fr] Pyrrolotriazines Substituées Par Hydroxyméthylaryle Utilisées Comme Inhibiteurs D'Alk1
标题: Hydroxymethylaryl-Substituted Pyrrolotriazines As Alk1 Inhibitors[fr] Pyrrolotriazines Substituées Par Hydroxyméthylaryle Utilisées Comme Inhibiteurs D'Alk1
摘要:这项发明涉及新型5-[(羟甲基)芳基]-取代吡咯并[2,1-F][1,2,4]三嗪-4-胺的化合物(I),以及制备这类化合物的方法,含有这类化合物的药物组合物,以及利用这类化合物或组合物治疗与血管反应生成相关的疾病,特别是与眼部血管反应生成相关的疾病.
海关参考信息
- 2905110000-甲醇
2933310010-吡啶
2939800000-其他生物碱 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9708336-B2
优先权日:2014-01-22
标题 :Metallo-beta-lactamase inhibitors
发明人：MANDAL MIHIR; TANG HAIFENG; XIAO LI; SU JING; LI GUOQING; YANG SHU-WEI; PAN WEIDONG; TANG HAIQUN; DEJESUS REYNALDA; HICKS JACQUELINE; LOMBARDO MATTHEW; CHU HONG; HAGMANN WILLIAM; PASTERNAK ALEX; GU XIN; JIANG JINLONG; DONG SHUZHI; DING FA-XIANG; LONDON CLARE; BISWAS DIPSHIKHA; YOUNG KATHERINE; HUNTER DAVID N; ZHAO ZHIQIANG; YANG DEXI
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.
专利号:WO-2010039922-A1
优先权日:2008-10-03
标 题:Calcilytic compounds
发明人：CASILLAS LINDA N; CHARNLEY ADAM KENNETH; DEMARTINO MICHAEL P; DONG XIAOYANG; HARRIS PHILIP ANTHONY; MARQUIS ROBERT W JR; RAMANJULU JOSHI M; TROUT ROBERT
权利人:GLAXOSMITHKLINE LLC; CASILLAS LINDA N; CHARNLEY ADAM KENNETH; DEMARTINO MICHAEL P; DONG XIAOYANG; HARRIS PHILIP ANTHONY; MARQUIS ROBERT W JR; RAMANJULU JOSHI M; TROUT ROBERT
摘要:Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.
专利号:US-8846910-B2
优先权日:2006-08-22
标题:Matrix metalloproteinase inhibitors
发明人：SATTIGERI VISWAJANANI J; PALLE VENKATA P; KHERA MANOJ KUMAR; REDDY RANADHEER; TIWARI MANOJ KUMAR; SONI AJAY; RAUF ABDUL REHMAN ABDUL; JOSEPH SONY; MUSIB ARPITA; DASTIDAR SUNANDA G; SRIVASTAVA PUNIT KUMAR
权利人:RANBAXY LAB LTD
摘要:The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.
